SOLID TUMOURS

Oncology Imaging is one of IAG’s special areas of therapeutic expertise and focus.  Oncology studies comprise almost one third of IAG’s clinical development experience. Currently IAG is engaged in trials with umbrella, adaptive and basket trial designs. IAG is providing full imaging service and image review in early and late phase trials, bringing our world-wide site network, operational expertise and technology platform DYNAMIKA to manage, collect, hold and score the imaging data.

A large proportion of our studies are the early clinical and phase II studies in solid tumours, lymphomas and brain tumours.

IAG’s radiology and analytics teams have hands-on experience with state-of-the-art imaging scoring systems and novel AI-driven methodologies. We have worked with studies requiring MRI, CT, X-ray, PET, immunoPET, SPECT, US, histology, and fluoroscopy imaging. Specifically, our team is board certified and experienced in:

• RECIST1.1, iRECIST, mRECIST, irRC, irRECIST,
• PERCIST and EORTC criteria for PET response,
• CHOI criteria for response to tumours,
• Macdonald, RANO, iRANO, mRANO and RAPNO for Neuro-Oncology,
• PIRADS and PCWG3 criteria for Prostate cancer,
• Cheson, Lugano and RECIL for lymphoma,
• Olsen criteria; IWCLL for CLL; MDA for bone metastases.

IAG’s team is an active scientific contributor and our work involved development of quantitative methodologies for

• Pseudo progression measurements
• Radiomic Analyses
• Quantitative assessment of the lesions (texture, shape, heterogeneity)
• Use of advanced imaging to assess the perfusion, hypoxia, cellular density of the tumours
• Macrophage Analysis
• Automated quantitation of total tumour burden and volumetric analysis
• Use of PET / SPECT novel agents for immune trafficking and receptor imaging

Our experts often use advanced functional imaging to aid early assessment of treatment response in oncology trials. These include:

• Perfusion measurements
• Diffusion and cellular density measurements
• Metabolic and proliferation assessments

We have experience with radiotherapies and advanced therapies, including

• Cellular therapy

• Viral therapy
• Intra tumoral injection
• Vaccines
• Combination studies
• Ablative therapy, radiation therapy
• Immune system stimulators
• Radiotherapies

IAG’s in-house radiologists and experts in Artificial Intelligence, Machine Learning and Big Data analytics can assist with all aspects of the imaging trial design, imaging data collection, site feasibility and training, image review and quantitative analysis.

We are proud to support you and bring real precision into the imaging trial, including understanding of pseudo progression and other complex manifestations of the disease in response to treatment.

Our partnerships with oncology focused companies have been published and are available to view on our website at ia-grp.com/trial-solutions/bio-partnering/

Reach out to our expert team, as you are designing and planning your trial.

About IAG, Image Analysis Group

IAG is a unique partner to life sciences companies developing new treatment and driving the hope of the up-coming precision medicine. IAG leverages expertise in medical imaging and the power of DYNAMIKA™, our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes.

Acting as imaging Contract Research Organization, IAG’s experts also recognize the significance of a comprehensive approach to asset development. They actively engage in co-development projects with both private and public sectors, demonstrating a commitment to cultivating collaboration and advancing healthcare solutions.

Contact our expert team: imaging.experts@ia-grp.com